Bibliografia   1. DJ Tenney, KA Pokornowski, RE Rose et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naïve patients. J Hepatol, Suppl 1, vol 50, 2009, Page S10 (abs 20)   2. M Lutgehetmann, J Schollmeyer, T Volz et al. Rescue therapy with combination of entecavir and tenofovir in patients with chronic HBV, advanced fibrosis and multiple previous treatment failures is safe and highly efficient. J Hepatol, Suppl 1, vol 50, 2009, Page S335 (abs 922)   3. CL Lai, R Elion, M Sherman, HW Hann et al, Entecavir therapy in chronic hepatitis B patients previously treated with adefovir with incomplete response on-treatment or relapse off-treatment. J Hepatol, Suppl 1, vol 50, 2009, Page S334 (abs 919)   4. P Marcellin, EJ Heathcote, I Jacobson, et al. Safety and tolerability of 96 weeks of tenofovir disoproxil fumavate treatment in HBeAg negative and positive patients infected with chronic hepatitis B. J Hepatol, Suppl 1, vol 50, 2009, Page S336 (abs 925)   5. M Buti, S Hadziyannis, P Mathurin et al. Two years safety and efficacy of tenofovir disoproxil fumarate in patients with HBV-induced cirrhosis. J Hepatol, Suppl 1, vol 50, 2009, Page S10 (abs 21)   6. K Wursthorn, M Jung, M Manns et al. Kinetics of HBsAg decline in HBeAg pos chronic hepatitis B patients with 3 years of telbivudine treatment duirng the GLOBE study. J Hepatol, Suppl 1, vol 50, 2009, Page S9 (abs 17)   7. Hadziyannis S, Sevastianos V, Rapti I. Outcome of HBeAg-negative chronic hepatitis B (CHB) 5 years after discontinuation of long term adefovir dipivoxil (ADV) treatment. J Hepatol, Suppl 1, vol 50, 2009, page S9 (abs 18)   8. Brown RS Jr, Buti M, Goodwin D et al. Hepatitis B virus (HBV) drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol, Suppl 1, vol 50, 2009, page S3 (abs 3)   9. M Viganò, P Lampertico, M Iavarone et al. High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B. J Hepatol, Suppl 1, vol 50, 2009, page S338 (abs 930)   10. P Marcellin, T Piratvisuth, M Brunetto et al. Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peg-interferon alfa-2a ± lamivudine: results of 5-year post-treatment follow-up. J Hepatol, Suppl 1, vol 50, 2009, pag S336 (abs 924)   11. GKK Lau, P Marcellin, M Brunetto et al. On-treatment monitoring of HBsAg levels to predict response to peginterferon alfa2a in patients with HBeAg-positive chronic hepatitis B. J Hepatol, Suppl 1, vol 50, 2009, pag S333 (abs 917)